ABL Diagnostics Société anonyme (EPA:ABLD)

France flag France · Delayed Price · Currency is EUR
2.500
-0.020 (-0.79%)
Jul 13, 2026, 5:21 PM CET
Market Cap40.17M -53.8%
Revenue (ttm)7.97M +35.7%
Net Income986.69K +246.0%
EPS0.06 +200.0%
Shares Out 16.07M
PE Ratio41.67
Forward PEn/a
Dividend0.11 (4.37%)
Ex-Dividend DateJul 3, 2026
Volume8,053
Open2.600
Previous Close2.520
Day's Range2.400 - 2.600
52-Week Range2.120 - 5.750
Beta-0.53
Analystsn/a
Price Targetn/a
Earnings DateSep 1, 2026

About EPA:ABLD

ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S RNA; ultragene assays for viral detection of SARS CoV-2, MonkeyPox, and Clostridium; microbiological specimen transport and collection kits, which inc... [Read more]

Sector Healthcare
CEO Chalom Sayada
Employees 22
Stock Exchange Euronext Paris
Ticker Symbol ABLD
Full Company Profile

Financial Performance

In 2025, EPA:ABLD's revenue was 7.97 million, an increase of 35.71% compared to the previous year's 5.87 million. Earnings were 986,693, an increase of 246.00%.

Financial Statements